US-based Berry Global Group plans to establish a second manufacturing facility and global healthcare centre of excellence in Bengaluru. Planned for development near Berry’s existing Bengaluru operation, the new facility will enable the company to extend its R&D expertise and scale up production in several key healthcare sectors: ophthalmic, nasal pumps, inhalation, and injectable administrations.

The increased capacity will also enhance supply in India and throughout South Asia, addressing some of the fastest growing healthcare market geographies.

“Investing in our global healthcare business in Bengaluru is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs,” remarked Tom Salmon, Chairman and CEO, Berry Global.

Alongside precision high-quality manufacturing equipment, the new facility will also house a dedicated R&D Center of Excellence (CoE). In addition to ensuring the dosing and administering of medicines are both easy and comfortable for the user, another critical design criterion will be to support customers' sustainability goals, with the existing Bengaluru facility already International Sustainability and Carbon Certificate (ISCC) Plus accredited. 

Construction of the new facility is expected to begin later this year, with the site validated and ready for production by the summer of 2023.